Something in the Air: Hyperoxic Conditioning of the Tumor Microenvironment for Enhanced Immunotherapy

Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel...

Full description

Saved in:
Bibliographic Details
Published inCancer cell Vol. 27; no. 4; pp. 435 - 436
Main Authors Leone, Robert D., Horton, Maureen R., Powell, Jonathan D.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 13.04.2015
Subjects
Animals
Antineoplastic Agents - therapeutic use
Female
Humans
Neoplasms - drug therapy
Neoplasms - immunology
Oxygen - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway. Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1535-6108
1878-3686
DOI:10.1016/j.ccell.2015.03.014